Outcomes of beta-blocker use in people living with chronic obstructive pulmonary disease and a co-existent beta-blocker indicated cardiovascular disease. Insights from a global federated network - Pub
2 hours ago
- #Beta-blockers
- #COPD
- #Cardiovascular Disease
- Beta-blockers (BBs) are crucial for managing cardiovascular diseases (CVD) like HFrEF, AMI, and AF.
- Use of BBs in COPD patients is controversial due to concerns about bronchoconstriction and respiratory side effects.
- Study assessed BB safety/effectiveness in COPD patients with CVD using real-world data from TriNetX network.
- Included 394,476 patients (241,837 BB users, 152,639 non-users) with COPD and CVD (HFrEF, AMI, or AF).
- No significant difference in all-cause mortality between BB users and non-users after propensity score matching.
- BB use linked to increased risk of emergency admissions (HR: 1.30) and modest rise in COPD exacerbations (HR: 1.03).
- Findings consistent across subgroups (cardiovascular indication, BB selectivity, sex, age).
- Conclusion: BBs in COPD patients with CVD showed no mortality benefit but increased risks of exacerbations and emergency admissions.
- Study used anonymized data, exempt from ethical approval and informed consent per HIPAA/GDPR regulations.
- Authors declared no competing interests.